NOVOLOG INNOLET (water injection) by Novo Nordisk. Approved for insulin analog [epc]. First approved in 2000.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
NOVOLOG INNOLET is a rapid-acting insulin analog injection approved in 2000 for subcutaneous administration. It is indicated for COPD management and works through insulin analog mechanism to regulate blood glucose. The product is formulated as an injectable solution delivered via the INNOLET pen device.
As LOE approaches, the brand team will likely transition toward lifecycle management and post-LOE sustainability strategies rather than growth initiatives.
Insulin Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Investigation of the Analgesic Effects of Intradermal and Subdermal Sterile Water Injection on Active Labor Pain
NOVOLOG INNOLET roles are primarily in mature commercial management, focused on defending market share and managing the transition to LOE. Career development on this product emphasizes lifecycle expertise and post-LOE strategy rather than innovation or expansion.
Worked on NOVOLOG INNOLET at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo